<DOC>
	<DOCNO>NCT01100112</DOCNO>
	<brief_summary>Open-label , 8 week study , assess efficacy safety oral Budesonide-MMX 9 mg Extended-release Tablets patient mild moderate , active ulcerative colitis remission base Ulcerative Colitis Disease Activity Index study CB-01-02/01 ( parent study [ NCT00679432 ] ) .</brief_summary>
	<brief_title>( CB-01-02/06 ) Oral Budesonide-Multi-Matrix System ( MMX ) 9mg Extended Release Tablets</brief_title>
	<detailed_description>Patients complete parent study achieve clinical remission eligible receive 8 week open-label treatment Budesonide-MMX 9mg satisfy entry criterion study .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female patient 18 74 year age , able understand voluntarily provide write informed consent Completed Final Visit assessment study CB0102/01 ( NCT00679432 ) clinical remission Diagnosis ulcerative colitis mild moderate severity Ulcerative Colitis Disease Activity Index ( UCDAI ) &lt; or= 10 accord Sutherland Females childbearing potential must serum pregnancy test perform Final Visit parent study , must use acceptable contraceptive method throughout treatment period . Female subject must also actively breastfeed entire study period . Ability comprehend full nature purpose study , include possible risk side effect Ability cooperate investigator comply requirement entire study Did complete study CB0102/01 Achieved clinical remission study CB0102/01 Patients severe ulcerative colitis ( UCDAI &gt; 10 ) Patients infectious colitis Evidence history toxic megacolon Severe anemia , leucopenia , granulocytopenia Use immunosuppressive agent last 8 week study use antitumor necrosis factor alpha agent last three month Concomitant use rectal preparation treatment ulcerative colitis Concomitant use antibiotic Concurrent use cytochrome P450 3A4 ( CYP3A4 ) inducer CYP3A4 inhibitor . Patients verify , presume expected pregnancy ongoing lactation Patients liver cirrhosis , evident hepatic renal disease insufficiency and/or severe impairment biohumoral parameter ( i.e. , 2x upper limit normal alanine aminotransferase , aspartate aminotransferase , gammaglutamyl transpeptidase , creatinine ) Patients severe disease ( ) organs system Patients local systemic complication pathological state require therapy corticosteroid and/or immunosuppressive agent Patients diagnose Type 1 diabetes Patients diagnose family history glaucoma Patients know hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) , accord local privacy policy Any medical condition principal investigator 's opinion would make administration study drug study procedures hazardous subject obscure interpretation adverse event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>ulcerative colitis</keyword>
	<keyword>Budesonide</keyword>
</DOC>